FDA DEVICE FACTS
Elecsys Anti-HBe, PreciControl Anti-HBe
Roche Diagnostics
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
Elecsys Anti-HBe Immunoassay for the in vitro qualitative detection of total antibodies to
hepatitis B e antigen (anti-HBe) in human adult serum or plasma (potassium EDTA, lithium heparin, sodium citrate, sodium heparin) from individuals with symptoms of hepatitis or at risk for hepatitis B virus (HBV) infection. Assay results, in conjunction with other laboratory results and clinical information may be used as an aid in the diagnosis of hepatitis B virus (HBV) infection in patients with symptoms of hepatitis or who may be at risk for HBV infection. A reactive test is presumptive laboratory evidence of HBV seroconversion. Further HBV serological marker testing is required to define the specific disease state.
The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 602 immunoassay analyzer.
PreciControl Anti-HBe
PreciControl Anti-HBe is used for quality control of the Elecsys Anti-HBe immunoassay on the cobas e 602 immunoassay analyzer. The performance of PreciControl Anti-HBe has not been established with any other anti-HBe assay.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。